Israeli - Kiingereza - Ministry of Health

neopharm ltd, israel - lonafarnib - hard gelatin capsules - lonafarnib 75 mg - lonafarnib - zokinvy is indicated in patients 12 months of age and older with a body surface area (bsa) of0.39 m2 and above:to reduce the risk of mortality in hutchinson-gilford progeria syndrome (hgps)• for the treatment of processing-deficient progeroid laminopathies with either:o heterozygous lmna mutation with progerin-like protein accumulationo homozygous or compound heterozygous zmpste24 mutationslimitations of usezokinvy is not indicated for other progeroid syndromes or processing-proficient progeroid laminopathies. based upon its mechanism of action, zokinvy would not be expected to be effective in these populations.